BeiGene Ltd.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 33
- Registration Number
- NCT05116085
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳The Affiliated Hospital of Qingdao University Branch South, Qingdao, Shandong, China
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 750
- Registration Number
- NCT05100862
- Locations
- 🇺🇸
Ucsf Fresno University of California San Francisco Fresno, Fresno, California, United States
🇺🇸Kaiser Permanente Southern California, Irvine, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 92
- Registration Number
- NCT05093270
- Locations
- 🇦🇺
Q PHARM, Herston, Queensland, Australia
🇦🇺Nucleus Network, Melbourne, Victoria, Australia
🇨🇳The Affiliated Hospital of Qingdao University Branch West Coast, Qingdao, Shandong, China
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
- Conditions
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 66
- Registration Number
- NCT05068440
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital, Hefei, Anhui, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 272
- Registration Number
- NCT05014815
- Locations
- 🇦🇺
Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia
🇦🇹Universitätsklinikum Krems, Krems, Krems an der Donau, Austria
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 58
- Registration Number
- NCT05014828
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical Hospital, Hefei, Anhui, China
🇨🇳Beijing Luhe Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 621
- Registration Number
- NCT05006716
- Locations
- 🇺🇸
Western Regional Medical Center, Llc, Goodyear, Arizona, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 70
- Registration Number
- NCT04974047
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 167
- Registration Number
- NCT04973605
- Locations
- 🇺🇸
City of Hope At Irvine Lennar, Irvine, California, United States
🇺🇸Southern Illinois University School of Medicine, Springfield, Illinois, United States
🇺🇸University of California At San Francisco, San Francisco, California, United States
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 126
- Registration Number
- NCT04952597
- Locations
- 🇨🇳
Mianyang Central Hospital, Mianyang, Sichuan, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Hwa Mei Hospital, University of Chinese Academy of Sciences, Zhejiang, China